Newer and upcoming therapies for melasma
- PMID: 22772611
- DOI: 10.4103/0378-6323.98071
Newer and upcoming therapies for melasma
Abstract
Melasma is one of the most common and distressing pigmentary disorders presenting to dermatology clinics. The precise cause of melasma remains unknown; however, there are many possible contributing factors. It is notably difficult to treat and has a tendency to relapse. The existing and most tried topical therapy is hydroquinone and the triple combination with tretinoin and corticosteroids, which is considered the gold standard for melasma. Besides that, azelaic acid, kojic acid, arbutin, ascorbic acid, glycolic acid and salicylic peels have also been tried with limited success. However, multiple novel topical agents are being investigated for their potential as hypopigmenting agents with unique mode of action. But, further trials are required to study their efficacy and safety before they can be further recommended. The article highlights these newer formulations and also briefly mentions about the newer chemical peels and the much hyped lasers in treating this difficult and frustrating condition.
Similar articles
-
Advances in the treatment of melasma: a review of the recent literature.Dermatol Surg. 2012 Jul;38(7 Pt 1):971-84. doi: 10.1111/j.1524-4725.2012.02435.x. Epub 2012 May 14. Dermatol Surg. 2012. PMID: 22583339 Review.
-
Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma.J Dermatol. 2007 Jan;34(1):25-30. doi: 10.1111/j.1346-8138.2007.00211.x. J Dermatol. 2007. PMID: 17204097 Clinical Trial.
-
Melasma. Etiologic and therapeutic considerations.Arch Dermatol. 1995 Dec;131(12):1453-7. doi: 10.1001/archderm.131.12.1453. Arch Dermatol. 1995. PMID: 7492140 Review.
-
Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study.J Cosmet Dermatol. 2007 Jun;6(2):89-94. doi: 10.1111/j.1473-2165.2007.00302.x. J Cosmet Dermatol. 2007. PMID: 17524124 Clinical Trial.
-
Utilizing combination therapy to optimize melasma outcomes.J Drugs Dermatol. 2004 Sep-Oct;3(5 Suppl):S27-34. J Drugs Dermatol. 2004. PMID: 15552597 Review.
Cited by
-
Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma.J Clin Aesthet Dermatol. 2016 Feb;9(2):48-57. J Clin Aesthet Dermatol. 2016. PMID: 27047632 Free PMC article. Review.
-
Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study.J Clin Aesthet Dermatol. 2018 Mar;11(3):14-19. Epub 2018 Mar 1. J Clin Aesthet Dermatol. 2018. PMID: 29606995 Free PMC article.
-
Skin Hyperpigmentation in Indian Population: Insights and Best Practice.Indian J Dermatol. 2016 Sep-Oct;61(5):487-95. doi: 10.4103/0019-5154.190103. Indian J Dermatol. 2016. PMID: 27688436 Free PMC article.
-
Tranexamic Acid in Melasma: Comparative Evaluation of Therapeutic Efficacy of Oral Tranexamic Acid versus Its Transepidermal Administration.J Cutan Aesthet Surg. 2022 Oct-Dec;15(4):394-399. doi: 10.4103/JCAS.JCAS_237_20. J Cutan Aesthet Surg. 2022. PMID: 37035597 Free PMC article.
-
Co-Treatment with Phlorotannin and Extracellular Vesicles from Ecklonia cava Inhibits UV-Induced Melanogenesis.Antioxidants (Basel). 2024 Mar 28;13(4):408. doi: 10.3390/antiox13040408. Antioxidants (Basel). 2024. PMID: 38671856 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources